(Q30412494)

21 June 2017

The interaction of metabolic factors with HCV infection: does it matter? (English)

1 reference

21 June 2017

1

Elisabetta Bugianesi

1 reference

21 June 2017

Federico Salamone

2

1 reference

PubMed ID

22300466

21 June 2017

Francesco Negro

series ordinal

3

1 reference

21 June 2017

1 January 2012

1 reference

21 June 2017

Journal of Hepatology

1 reference

21 June 2017

56 Suppl 1

1 reference

21 June 2017

S56-65

1 reference

Global and societal implications of the diabetes epidemic

21 June 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2812%2960007-5

7 January 2021

Evolving epidemiology of hepatitis C virus

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2812%2960007-5

7 January 2021

Aging of hepatitis C virus (HCV)-infected persons in the United States: a multiple cohort model of HCV prevalence and disease progression

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2812%2960007-5

7 January 2021

Increasing prevalence of HCC and cirrhosis in patients with chronic hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2812%2960007-5

7 January 2021

Current understanding of insulin resistance in hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2812%2960007-5

7 January 2021

Abnormalities of lipid metabolism in hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2812%2960007-5

7 January 2021

Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III)

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2812%2960007-5

7 January 2021

The metabolic syndrome--a new worldwide definition

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2812%2960007-5

7 January 2021

Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; Internat

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2812%2960007-5

7 January 2021

Prevalence of type 2 diabetes mellitus among persons with hepatitis C virus infection in the United States

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2812%2960007-5

7 January 2021

Hepatitis C virus infection and incident type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2812%2960007-5

7 January 2021

New onset diabetes mellitus after liver transplantation and hepatitis C virus infection: meta-analysis of clinical studies

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2812%2960007-5

7 January 2021

The impact of diabetes mellitus on fibrosis progression in patients transplanted for hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2812%2960007-5

7 January 2021

Risk factors and consequences of post-transplant diabetes mellitus.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2812%2960007-5

7 January 2021

Hepatitis C virus infection and post-transplant diabetes mellitus among renal transplant patients: a meta-analysis.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2812%2960007-5

7 January 2021

Insulin resistance is associated with chronic hepatitis C virus infection and fibrosis progression [corrected].

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2812%2960007-5

7 January 2021

Insulin resistance in chronic hepatitis C: association with genotypes 1 and 4, serum HCV RNA level, and liver fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2812%2960007-5

7 January 2021

Clearance of HCV improves insulin resistance, beta-cell function, and hepatic expression of insulin receptor substrate 1 and 2.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2812%2960007-5

7 January 2021

Effect of sustained virological response to treatment on the incidence of abnormal glucose values in chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2812%2960007-5

7 January 2021

Sustained virological response reduces incidence of onset of type 2 diabetes in chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2812%2960007-5

7 January 2021

Incidence of type 2 diabetes mellitus and glucose abnormalities in patients with chronic hepatitis C infection by response to treatment: results of a cohort study

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2812%2960007-5

7 January 2021

Homeostasis model assessment: insulin resistance and ?-cell function from fasting plasma glucose and insulin concentrations in man

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2812%2960007-5

7 January 2021

Insulin resistance: a metabolic pathway to chronic liver disease

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2812%2960007-5

7 January 2021

Comparison of surrogate and direct measurement of insulin resistance in chronic hepatitis C virus infection: impact of obesity and ethnicity

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2812%2960007-5

7 January 2021

Sites and mechanisms of insulin resistance in nonobese, nondiabetic patients with chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2812%2960007-5

7 January 2021

Chronic hepatitis C is associated with peripheral rather than hepatic insulin resistance.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2812%2960007-5

7 January 2021

Hepatitis C virus infection and diabetes: direct involvement of the virus in the development of insulin resistance

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2812%2960007-5

7 January 2021

From mice to men: insights into the insulin resistance syndromes

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2812%2960007-5

7 January 2021

Inhibition of the protein tyrosine phosphatase PTP1B: potential therapy for obesity, insulin resistance and type-2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2812%2960007-5

7 January 2021

PTEN and SHIP2 phosphoinositide phosphatases as negative regulators of insulin signalling.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2812%2960007-5

7 January 2021

SOCS-1 and SOCS-3 block insulin signaling by ubiquitin-mediated degradation of IRS1 and IRS2

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2812%2960007-5

7 January 2021

Cellular mechanisms of insulin resistance: role of stress-regulated serine kinases and insulin receptor substrates (IRS) serine phosphorylation

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2812%2960007-5

7 January 2021

Protein-protein interaction in insulin signaling and the molecular mechanisms of insulin resistance

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2812%2960007-5

7 January 2021

Impaired IRS-1/PI3-kinase signaling in patients with HCV: a mechanism for increased prevalence of type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2812%2960007-5

7 January 2021

Hepatitis C Virus Down-Regulates Insulin Receptor Substrates 1 and 2 through Up-Regulation of Suppressor of Cytokine Signaling 3

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2812%2960007-5

7 January 2021

The hepatitis C virus core protein of genotypes 3a and 1b downregulates insulin receptor substrate 1 through genotype-specific mechanisms

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2812%2960007-5

7 January 2021

Hepatitis C virus core protein genotype 3a increases SOCS-7 expression through PPAR-{gamma} in Huh-7 cells

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2812%2960007-5

7 January 2021

Effects of hepatitis C virus on suppressor of cytokine signaling mRNA levels: comparison between different genotypes and core protein sequence analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2812%2960007-5

7 January 2021

Non-response to antiviral therapy is associated with obesity and increased hepatic expression of suppressor of cytokine signalling 3 (SOCS-3) in patients with chronic hepatitis C, viral genotype 1

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2812%2960007-5

7 January 2021

Involvement of the PA28 -Dependent Pathway in Insulin Resistance Induced by Hepatitis C Virus Core Protein

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2812%2960007-5

7 January 2021

Critical role of PA28 in hepatitis C virus-associated steatogenesis and hepatocarcinogenesis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2812%2960007-5

7 January 2021

Virus-induced over-expression of protein phosphatase 2A inhibits insulin signalling in chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2812%2960007-5

7 January 2021

Upregulation of protein phosphatase 2Ac by hepatitis C virus modulates NS3 helicase activity through inhibition of protein arginine methyltransferase 1.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2812%2960007-5

7 January 2021

Protein phosphatase 2A negatively regulates insulin's metabolic signaling pathway by inhibiting Akt (protein kinase B) activity in 3T3-L1 adipocytes

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2812%2960007-5

7 January 2021

Activation of endoplasmic reticulum stress response by hepatitis viruses up-regulates protein phosphatase 2A.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2812%2960007-5

7 January 2021

Hepatitis C virus core protein upregulates serine phosphorylation of insulin receptor substrate-1 and impairs the downstream akt/protein kinase B signaling pathway for insulin resistance

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2812%2960007-5

7 January 2021

Hepatic insulin resistance is associated with increased apoptosis and fibrogenesis in nonalcoholic steatohepatitis and chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2812%2960007-5

7 January 2021

Increased serum interleukin-18 concentration is associated with hypoadiponectinemia in obesity, independently of insulin resistance

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2812%2960007-5

7 January 2021

Adiponectin blocks interleukin-18-mediated endothelial cell death via APPL1-dependent AMP-activated protein kinase (AMPK) activation and IKK/NF-kappaB/PTEN suppression

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2812%2960007-5

7 January 2021

SOCS-3 inhibits insulin signaling and is up-regulated in response to tumor necrosis factor-alpha in the adipose tissue of obese mice

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2812%2960007-5

7 January 2021

Soluble tumor necrosis factor receptors in chronic hepatitis C: a correlation with histological fibrosis and activity

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2812%2960007-5

7 January 2021

Plasma leptin and TNF-alpha levels in chronic hepatitis C patients and their relationship to hepatic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2812%2960007-5

7 January 2021

Mechanisms of increased insulin resistance in non-cirrhotic patients with chronic hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2812%2960007-5

7 January 2021

Insulin resistance and liver injury in hepatitis C is not associated with virus-specific changes in adipocytokines

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2812%2960007-5

7 January 2021

Molecular diagnosis of hypobetalipoproteinemia: an ENID review

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2812%2960007-5

7 January 2021

Hepatitis C, metabolic syndrome, and inflammatory markers: results from the Third National Health and Nutrition Examination Survey [NHANES III].

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2812%2960007-5

7 January 2021

Histologic observations in human hepatitis non-A, non-B

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2812%2960007-5

7 January 2021

Host- and disease-specific factors affecting steatosis in chronic hepatitis C

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2812%2960007-5

7 January 2021

Prevalence of liver steatosis in patients with chronic hepatitis B: a study of associated factors and of relationship with fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2812%2960007-5

7 January 2021

Hepatic steatosis in chronic hepatitis B patients is associated with metabolic factors more than viral factors

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2812%2960007-5

7 January 2021

Hepatocyte steatosis is a cytopathic effect of hepatitis C virus genotype 3.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2812%2960007-5

7 January 2021

Steatosis accelerates the progression of liver damage of chronic hepatitis C patients and correlates with specific HCV genotype and visceral obesity

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2812%2960007-5

7 January 2021

Hepatitis C virus genotype 3 is cytopathic to hepatocytes: Reversal of hepatic steatosis after sustained therapeutic response

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2812%2960007-5

7 January 2021

Effect of treatment with peginterferon or interferon alfa-2b and ribavirin on steatosis in patients infected with hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2812%2960007-5

7 January 2021

An in vitro model of hepatitis C virus genotype 3a-associated triglycerides accumulation

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2812%2960007-5

7 January 2021

Specific Polymorphisms in Hepatitis C Virus Genotype 3 Core Protein Associated with Intracellular Lipid Accumulation

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2812%2960007-5

7 January 2021

Morphological changes in intracellular lipid droplets induced by different hepatitis C virus genotype core sequences and relationship with steatosis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2812%2960007-5

7 January 2021

Hepatitis C virus core protein induces hepatic steatosis in transgenic mice

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2812%2960007-5

7 January 2021

Hepatitis C virus core protein inhibits microsomal triglyceride transfer protein activity and very low density lipoprotein secretion: a model of viral-related steatosis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2812%2960007-5

7 January 2021

Steatosis and liver cancer in transgenic mice expressing the structural and nonstructural proteins of hepatitis C virus

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2812%2960007-5

7 January 2021

Hepatitis C virus core protein modulates fatty acid metabolism and thereby causes lipid accumulation in the liver

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2812%2960007-5

7 January 2021

Investigation of the role of SREBP-1c in the pathogenesis of HCV-related steatosis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2812%2960007-5

7 January 2021

Interaction of hepatitis C virus core protein with retinoid X receptor alpha modulates its transcriptional activity

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2812%2960007-5

7 January 2021

Nonlinear partial differential equations and applications: Genomic analysis of the host response to hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2812%2960007-5

7 January 2021

Up-regulation of fatty acid synthase promoter by hepatitis C virus core protein: genotype-3a core has a stronger effect than genotype-1b core

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2812%2960007-5

7 January 2021

Hepatitis C Virus Induces Proteolytic Cleavage of Sterol Regulatory Element Binding Proteins and Stimulates Their Phosphorylation via Oxidative Stress

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2812%2960007-5

7 January 2021

Hepatitis C Virus Proteins Induce Lipogenesis and Defective Triglyceride Secretion in Transgenic Mice

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2812%2960007-5

7 January 2021

Hepatitis C virus induced hypobetalipoproteinemia: a possible mechanism for steatosis in chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2812%2960007-5

7 January 2021

Hepatocellular fat accumulation and low serum cholesterol in patients infected with HCV-3a

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2812%2960007-5

7 January 2021

Liver microsomal triglyceride transfer protein is involved in hepatitis C liver steatosis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2812%2960007-5

7 January 2021

Impaired expression of the peroxisome proliferator-activated receptor alpha during hepatitis C virus infection.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2812%2960007-5

7 January 2021

Peroxisome proliferator-activated receptor-alpha and -gamma mRNA levels are reduced in chronic hepatitis C with steatosis and genotype 3 infection

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2812%2960007-5

7 January 2021

Hepatitis C virus infection down-regulates the expression of peroxisome proliferator-activated receptor alpha and carnitine palmitoyl acyl-CoA transferase 1A.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2812%2960007-5

7 January 2021

The genotype 3-specific hepatitis C virus core protein residue phenylalanine 164 increases steatosis in an in vitro cellular model

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2812%2960007-5

7 January 2021

Viral genotype-specific role of PNPLA3, PPARG, MTTP, and IL28B in hepatitis C virus-associated steatosis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2812%2960007-5

7 January 2021

Insulin resistance is a cause of steatosis and fibrosis progression in chronic hepatitis C

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2812%2960007-5

7 January 2021

Serum HCV RNA levels and HCV genotype do not affect insulin resistance in nondiabetic patients with chronic hepatitis C: a multicentre study.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2812%2960007-5

7 January 2021

Central role of suppressors of cytokine signaling proteins in hepatic steatosis, insulin resistance, and the metabolic syndrome in the mouse

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2812%2960007-5

7 January 2021

Liver fibrosis is not associated with steatosis but with necroinflammation in French patients with chronic hepatitis C

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2812%2960007-5

7 January 2021

Down-regulation of phosphatase and tensin homolog by hepatitis C virus core 3a in hepatocytes triggers the formation of large lipid droplets.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2812%2960007-5

7 January 2021

Hepatitis B and C virus infection and the risk of atherosclerosis in a general population

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2812%2960007-5

7 January 2021

Differences and similarities in early atherosclerosis between patients with non-alcoholic steatohepatitis and chronic hepatitis B and C

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2812%2960007-5

7 January 2021

Hepatitis C infection and clearance: impact on atherosclerosis and cardiometabolic risk factors

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2812%2960007-5

7 January 2021

HCV infection facilitates asymptomatic carotid atherosclerosis: preliminary report of HCV RNA localization in human carotid plaques.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2812%2960007-5

7 January 2021

Components of metabolic syndrome are independent predictors of mortality in patients with chronic liver disease: a population-based study

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2812%2960007-5

7 January 2021

Overweight, obesity and risk of liver cancer: a meta-analysis of cohort studies

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2812%2960007-5

7 January 2021

Metabolic factors and risk of hepatocellular carcinoma by chronic hepatitis B/C infection: a follow-up study in Taiwan.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2812%2960007-5

7 January 2021

Insulin resistance, serum leptin, and adiponectin levels and outcomes of viral hepatitis C cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2812%2960007-5

7 January 2021

Relationship between steatosis, inflammation, and fibrosis in chronic hepatitis C: a meta-analysis of individual patient data.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2812%2960007-5

7 January 2021

Genotype 3 is associated with accelerated fibrosis progression in chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2812%2960007-5

7 January 2021

Role of hepatitis C virus genotype 3 in liver fibrosis progression--a systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2812%2960007-5

7 January 2021

Fibrosis in genotype 3 chronic hepatitis C and nonalcoholic fatty liver disease: Role of insulin resistance and hepatic steatosis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2812%2960007-5

7 January 2021

Post-load insulin resistance is an independent predictor of hepatic fibrosis in virus C chronic hepatitis and in non-alcoholic fatty liver disease

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2812%2960007-5

7 January 2021

High glucose and hyperinsulinemia stimulate connective tissue growth factor expression: a potential mechanism involved in progression to fibrosis in nonalcoholic steatohepatitis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2812%2960007-5

7 January 2021

Progression of liver fibrosis in women infected with hepatitis C: long-term benefit of estrogen exposure.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2812%2960007-5

7 January 2021

Liver fibrosis in women with chronic hepatitis C: evidence for the negative role of the menopause and steatosis and the potential benefit of hormone replacement therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2812%2960007-5

7 January 2021

Early menopause is associated with lack of response to antiviral therapy in women with chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2812%2960007-5

7 January 2021

Impact of insulin resistance on sustained response in HCV patients treated with pegylated interferon and ribavirin: a meta-analysis.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2812%2960007-5

7 January 2021

p21-activated kinase 1 is activated through the mammalian target of rapamycin/p70 S6 kinase pathway and regulates the replication of hepatitis C virus in human hepatoma cells

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2812%2960007-5

7 January 2021

Genetics of metabolic syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2812%2960007-5

7 January 2021

Metabolic syndrome: from the genetics to the pathophysiology

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2812%2960007-5

7 January 2021

Pioglitazone in chronic hepatitis C not responding to pegylated interferon-alpha and ribavirin

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2812%2960007-5

7 January 2021

Pioglitazone improves virological response to peginterferon alpha-2b/ribavirin combination therapy in hepatitis C genotype 4 patients with insulin resistance

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2812%2960007-5

7 January 2021

Treatment of insulin resistance with metformin in naïve genotype 1 chronic hepatitis C patients receiving peginterferon alfa-2a plus ribavirin

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2812%2960007-5

7 January 2021

10.1016/S0168-8278(12)60007-5

Identifiers

DOI

1 reference

21 June 2017

1 reference

PubMed ID

22300466